Where is Fair Value?, page-2

First 2 Last

Share
Profile

Follow
stardestr0yer

7,949 Posts.

456

06/03/20

13:07

Post #: 43342781
Share

Originally posted by T.E.P.: ↑

I'm as stunned as everyone else that at the time of writting, you can pick up shares in 1ST for 3.6c, which values the entire business at just $15M.

But, investors overall appear to have lost complete faith in the growth trajectory of this business. 1ST is currently priced as a low growth business (<15% CAGR), which is evidently below the historical organic growth rate (35% CAGR).

A SaaS company of this size growing at a 30% CAGR traditionally would trade on 5x ARR which would be a market cap of $26M. That would be a share price of 6.1 cents. To be completepy frank, I think historical performance alone (major deals aside) puts current fair value for 1ST at no less than 6.1 cents, assuming 30% top line growth continues as the baseline.

But, going forward beyond 6 cents, it all comes down to execution. To take us back to 7-10c levels and beyond, Klaus needs to deliver some form of accelerated growth, which the market is no longer pricing into the share price.

If Q3 and Q4 do not deliver any form of accelerated growth above the 30% CAGR baseline then I will be the first to admit that returning to 10 cents looks unlikely.

I'm not expecting a huge surge in growth in either Q3 or Q4 but I am expecting to see some very solid growth that is accelerating. This acceleration of growth needs to be driven by a higher ARPU, increased sites (currently climbing at ~2000 per year) and the network effect. I'm predicting CY2020 to add ~3,500 sites.

In summary, given where we are now with the share price, confidence appears to have been lost. The current share price assumes extremely minimal growth going forward. Only time will tell, but I believe we will be back at fair value of 6 cents (at least) in the short term.

T.E.P.

Expand

"I'm not expecting a huge surge in growth in either Q3 or Q4 but I am expecting to see some very solid growth that is accelerating. "

I am expecting a definite surge and will be disappointed with anything less than 20% for this quarter alone. 1ST increased ARR by 7% in first 2 weeks of Jan alone. Since ARR being reported the best we have has is 16%. Expecting the Q4 to have very similar QOQ growth.

1ST Price at posting: 3.7¢ Sentiment: Hold Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

PL3

Patagonia looks to raise $2.15M for South American exploration and development

There are more pages in this discussion • 71 more messages in this thread...

First 2 Last

Add VFX (ASX) to my watchlist

(20min delay)
Last 0.5¢		Change 0.000(0.00%)		Mkt cap ! $7.5M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
11	11076656	0.4¢

Sellers (Offers)

Price($)	Vol.	No.
0.5¢	5749999	5

View Market Depth

No.	Vol.	Price($)
11	11076656	0.004
3	5286288	0.003
3	2950000	0.002
3	3200000	0.001
0	0	0.000

Price($)	Vol.	No.
0.005	5749999	5
0.006	913079	3
0.007	500000	1
0.008	715000	2
0.030	30730	1

Last trade - 16.12pm 09/07/2024 (20 minute delay)

VFX (ASX) Chart

Day chart unavailable

Where is Fair Value?, page-2

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Patagonia looks to raise $2.15M for South American exploration and development

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Where is Fair Value?, page-2

Top Stories

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Patagonia looks to raise $2.15M for South American exploration and development

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News